Aura Biosciences to Participate in Upcoming Investor Conferences
November 03 2022 - 7:00AM
Business Wire
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced that members of its executive team will participate in
the following upcoming investor conferences:
- Stifel 2022 Healthcare Conference at the Lotte New York
Palace on Wednesday, November 16, 2022. Presentation at 10:55
a.m. ET.
- 5th Annual 2022 Evercore ISI HealthCONx on Tuesday, November
29, 2022. Fireside chat at 8:25 a.m. ET.
A live webcast of the Stifel presentation and Evercore ISI
fireside chat will be available on the “Investors & Media” page
under the “Events & Presentations” section of the Company’s
website at https://ir.aurabiosciences.com/events-and-presentations,
where a replay of the webcasts will be archived for 90 days
following the presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing virus-like drug conjugates (VDCs), a novel class of
therapies, for the treatment of multiple oncology indications.
Aura’s lead VDC candidate, belzupacap sarotalocan (Bel-sar;
AU-011), consists of a virus-like particle conjugated with an
anti-cancer agent. Belzupacap sarotalocan is designed to
selectively target and destroy cancer cells and activate the immune
system with the potential to create long-lasting anti-tumor
immunity. Belzupacap sarotalocan is currently in development for
ocular cancers, with an ongoing Phase 2 dose escalation clinical
trial evaluating first-line treatment of choroidal melanoma, a
vision- and life-threatening form of eye cancer where standard of
care with radiotherapy leaves patients with severe comorbidities,
including major vision loss. Aura plans to pursue development of
belzupacap sarotalocan across its ocular oncology franchise
including for the treatment of patients with choroidal metastasis.
In addition, leveraging Aura’s technology platform, Aura is
developing belzupacap sarotalocan more broadly across multiple
cancers, including in patients with non-muscle invasive bladder
cancer (NMIBC). Aura is headquartered in Boston, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221103005314/en/
Investor and Media Contact: Alex Dasalla Head of Investor
Relations and Corporate Communications
adasalla@aurabiosciences.com
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2023 to Apr 2024